肝细胞癌:当前的治疗管理与未来展望。

Hepatocellular carcinoma: current management and perspectives for the future.

机构信息

Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany.

出版信息

Ann Surg. 2011 Mar;253(3):453-69. doi: 10.1097/SLA.0b013e31820d944f.

Abstract

OBJECTIVE

To review the literature on current management of hepatocellular carcinoma (HCC).

BACKGROUND

Hepatocellular carcinoma represents one of the most common malignancies worldwide with a rising incidence in western countries. There have been substantial advances in the surgical and medical treatment of HCC within the past 2 decades.

METHODS

A literature review was performed in the MEDLINE database to identify studies on the management of HCC. On the basis of the available evidence recommendations for practice were graded using the Oxford Centre for Evidence-based Medicine classification.

RESULTS

Advances in surgical technique and perioperative care have established surgical resection and orthotopic liver transplantation (OLT) as primary curative therapy for HCC in noncirrhotic and cirrhotic patients, respectively. Primary resection and salvage OLT may be indicated in cirrhotics with preserved liver function. Selection criteria for OLT remain debated, as slight expansion of the Milan criteria may not worsen prognosis but is limited by organ shortage and prolonged waiting time with less favorable outcome on intention-to-treat analyses. Strategies of neoadjuvant treatment before OLT require evaluation within prospective trials. Transarterial chemoembolization is the primary therapy in patients with inoperable HCC and compensated liver function. Although systemic chemotherapy is not effective in patients with advanced HCC, there is recent evidence that these patients benefit from new molecular targeted therapies. If these agents are also effective in the neoadjuvant and adjuvant setting is currently being investigated. Furthermore, selective intra-arterial radiation therapy represents a promising new approach for treatment of unresectable HCC.

CONCLUSIONS

Recent developments in the surgical and medical therapy have significantly improved outcome of patients with operable and advanced HCC. A multidisciplinary approach seems essential to further improve patients' prognosis.

摘要

目的

回顾当前肝细胞癌(HCC)治疗的文献。

背景

肝细胞癌是全球最常见的恶性肿瘤之一,西方国家的发病率呈上升趋势。在过去的 20 年中,HCC 的外科和内科治疗取得了实质性进展。

方法

在 MEDLINE 数据库中进行文献回顾,以确定 HCC 治疗的研究。根据现有证据,使用牛津循证医学中心分类对实践建议进行分级。

结果

手术技术和围手术期护理的进步使手术切除和原位肝移植(OLT)分别成为非肝硬化和肝硬化患者 HCC 的主要治愈性治疗方法。对于肝功能正常的肝硬化患者,可以考虑进行原发性切除和挽救性 OLT。OLT 的选择标准仍存在争议,因为米兰标准的略微扩展可能不会恶化预后,但由于器官短缺和等待时间延长,以及意向治疗分析中预后较差,其应用受到限制。OLT 前新辅助治疗策略需要在前瞻性试验中进行评估。经动脉化疗栓塞是不可切除 HCC 和代偿性肝功能患者的主要治疗方法。虽然晚期 HCC 患者的全身化疗无效,但最近有证据表明这些患者受益于新的分子靶向治疗。这些药物在新辅助和辅助治疗中的有效性目前正在研究中。此外,选择性动脉内放射治疗代表了治疗不可切除 HCC 的一种很有前途的新方法。

结论

外科和内科治疗的新进展显著改善了可手术和晚期 HCC 患者的预后。多学科方法似乎对于进一步改善患者的预后至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索